EP3972589 - NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 31.05.2024 Database last updated on 03.09.2024 | |
Former | Grant of patent is intended Status updated on 07.02.2024 | ||
Former | Request for examination was made Status updated on 25.02.2022 | ||
Former | The international publication has been made Status updated on 27.11.2020 | Most recent event Tooltip | 31.05.2024 | (Expected) grant | published on 03.07.2024 [2024/27] | Applicant(s) | For all designated states Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, New Jersey 07065 / US | [2022/42] |
Former [2022/13] | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Road Rahway, New Jersey 07065-0907 / US | Inventor(s) | 01 /
BENNETT, Frank 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 02 /
IMBRIGLIO, Jason, E. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 03 /
KEREKES, Angela, D. 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 04 /
KHAN, Tanweer 21 Forest Avenue Bridgewater, New Jersey 08807 / US | 05 /
LANKIN, Claire 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 06 /
LI, Derun 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 07 /
WU, Zhicai 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 08 /
XIONG, Yusheng 60 Bradford Lane Plainsboro, New Jersey 08536 / US | 09 /
YOUM, Hyewon 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 10 /
YU, Yang 2000 Galloping Hill Road Kenilworth, New Jersey 07033 / US | 11 /
KURISSERY, Anthappan Tony Flat F3-802, SNN RAJ Greenbay Apartments 1st Main Road Near Tech Mahindra Electronic City Phase II Bangalore 560100 / IN | 12 /
KOMANDURI, Venukrishnan 21 Egerton Court Upper Park Road Manchester M14 5SL / GB | 13 /
YE, Feng deceased / US | [2022/13] | Representative(s) | Merck Sharp & Dohme LLC 120 Moorgate London EC2M 6UR / GB | [2024/27] |
Former [2022/13] | Jaap, David Robert Merck Sharp & Dohme Corp. 120 Moorgate London, EC2M 6UR / GB | Application number, filing date | 20808662.9 | 18.05.2020 | [2022/13] | WO2020US33356 | Priority number, date | US201962851534P | 22.05.2019 Original published format: US 201962851534 P | [2022/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020236690 | Date: | 26.11.2020 | Language: | EN | [2020/48] | Type: | A1 Application with search report | No.: | EP3972589 | Date: | 30.03.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.11.2020 takes the place of the publication of the European patent application. | [2022/13] | Type: | B1 Patent specification | No.: | EP3972589 | Date: | 03.07.2024 | Language: | EN | [2024/27] | Search report(s) | International search report - published on: | US | 26.11.2020 | (Supplementary) European search report - dispatched on: | EP | 23.03.2023 | Classification | IPC: | A61P13/12, A61P3/10, C07D401/12, C07D401/14, C07D413/14, C07D487/10, C07D491/107, C07D498/08, A61K31/435 | [2023/17] | CPC: |
A61P3/10 (EP);
C07D491/107 (EP,US);
A61K45/06 (US);
A61P13/12 (EP);
C07D401/12 (EP);
C07D401/14 (EP,US);
| C-Set: |
A61K31/473, A61K2300/00 (EP);
A61K31/501, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP)
|
Former IPC [2022/13] | A61K31/41, A61K31/415, A61K31/155 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/13] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | NATRIURETISCHE PEPTID-REZEPTOR-A-AGONISTEN ZUR BEHANDLUNG VON KARDIOMETABOLISCHEN ERKRANKUNGEN, NIERENERKRANKUNGEN UND DIABETES | [2022/13] | English: | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | [2022/13] | French: | AGONISTES DU RÉCEPTEUR DU PEPTIDE NATRIURÉTIQUE A UTILES POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES, DE MALADIES RÉNALES ET DU DIABÈTE | [2022/13] | Entry into regional phase | 22.12.2021 | National basic fee paid | 22.12.2021 | Search fee paid | 22.12.2021 | Designation fee(s) paid | 22.12.2021 | Examination fee paid | Examination procedure | 22.12.2021 | Examination requested [2022/13] | 04.10.2023 | Amendment by applicant (claims and/or description) | 08.02.2024 | Communication of intention to grant the patent | 24.05.2024 | Fee for grant paid | 24.05.2024 | Fee for publishing/printing paid | 24.05.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 21.03.2022 | Renewal fee patent year 03 | 21.03.2023 | Renewal fee patent year 04 | 18.03.2024 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2018175534 (PHARMAIN CORP [US]); | [E]WO2020236688 (MERCK SHARP & DOHME [US], et al) | International search | [A]WO2018057618 (DANA FARBER CANCER INST INC [US], et al); | [A]WO2018098473 (DANA FARBER CANCER INST INC [US], et al); | by applicant | US4845079 | US4885292 | US4894437 | US4980283 | US5034512 | US5036054 | US5036053 | US5055466 | US5063208 | US5063207 | US5064965 | US5066643 | US5071837 | US5075451 | US5089471 | US5095119 | US5098924 | US5104869 | US5106835 | US5114937 | US5116835 | WO9728149 | WO0208188 | WO2004020408 | WO2004020409 | WO2010039789 | WO2018175534 | WO2020236688 |